Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with highly chemorefractory Hodgkin lymphoma (HL). The CD30-targeting antibody-drug conjugate Brentuximab-Vedotin (BV) and programmed cell death protein-1 (PD-1) blocking agents hav...

詳細記述

書誌詳細

出版年:	Frontiers in Immunology
主要な著者:	Federica Giannotti, Carmen De Ramon Ortiz, Federico Simonetta, Sarah Morin, Chiara Bernardi, Stavroula Masouridi-Levrat, Yves Chalandon, Anne-Claire Mamez
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2024-03-01
主題:	Hodgkin lymphoma pembrolizumab brentuximab-vedotin haploidentical allogeneic stem cell transplant DLI
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1360275/full